of Recommendations Squamous Intraepithelial Lesions, Work Group (WG)2 1. A unified histopathologic nomenclature with a single set of diagnostic terms is recommended for all human papillomavirus (HPV)-associated preinvasive squamous lesions of the lower anogenital tract (LAT). 2. A two-tiered nomenclature is recommended for noninvasive HPV-associated squamous proliferations of the LAT, which may be further qualified with the appropriate -IN (intraepithelial neoplasia) terminology. Comment: -IN refers to the generic intraepithelial neoplasia terminology, without specifying the location. For a specific location, the appropriate complete term should be used. Thus, for an -IN 3 lesion: cervix = CIN 3, vagina = VaIN 3, vulva = VIN 3, anus = AIN 3, perianus = PAIN 3, and penis = PeIN 3.
penile carcinoma.
2. For cases of invasive squamous carcinoma with positive biopsy/resection margins, the pathology report should state whether:
The examined invasive tumor exceeds the dimensions for a SISCCA (defined below) OR The examined invasive tumor component is less than or equal to the dimensions for a SISCCA and conclude that the tumor is "At least a superficially invasive squamous carcinoma" 3. In cases of SISCCA, the following parameters should be included in the pathology report:
The presence or absence of LVI. The presence, number, and size of independent multifocal carcinomas (after excluding the possibility of a single carcinoma) 4. Cervix: SISCCA of the cervix is defined as an invasive squamous carcinoma that:
Is not a grossly visible lesion, AND Has an invasive depth of ≤3 mm from the basement membrane of the point of origin, AND Has a horizontal spread of ≤7 mm in maximal extent, AND Has been completely excised 5. Vagina: No recommendation is offered for early invasive squamous carcinoma of the vagina.
Comment: Owing to the rarity of primary SCC of the vagina, there are insufficient data to define early invasive squamous carcinoma in the vagina.
6. Anal canal: The suggested definition of SISCCA of the anal canal is an invasive squamous carcinoma that:
Has an invasive depth of ≤3 mm from the basement membrane of the point of origin, AND Has a horizontal spread of ≤7 mm in maximal extent, AND Has been completely excised 7. Vulva: Vulvar SISCCA is defined as an American Joint Committee on Cancer (AJCC) T1a (International Federation of Gynecology Tumor that invades only the subepithelial connective tissue, AND No LVI AND Is not poorly differentiated (i.e., grade 3-4) 9. Scrotum: No recommendation is offered for early invasive squamous carcinoma of the scrotum.
Comment: Owing to the rarity of primary SCC of the scrotum, there is insufficient literature to make a recommendation regarding the current AJCC staging of early scrotal cancers.
Perianus:
The suggested definition for SISCCA of the perianus is an invasive squamous carcinoma that:
Has an invasive depth of ≤3 mm from the basement membrane of the point of origin, AND Has a horizontal spread of ≤7 mm in maximal extent, AND Has been completely excised Biomarkers in HPV-Associated Lower Anogenital Squamous Lesions, WG4
1. p16 immunohistochemical is recommended when the hematoxylin and eosin (H&E) morphologic differential diagnosis is between precancer (-IN 2 or -IN 3) and a mimic of precancer (e.g., processes known to be not related to neoplastic risk such as immature squamous metaplasia, atrophy, reparative epithelial changes, tangential cutting). Comment: Strong and diffuse block-positive p16 results support a categorization of precancerous disease.
2. If the pathologist is entertaining an H&E morphologic interpretation of -IN 2 (under the old terminology, which is a biologically equivocal lesion falling between the morphologic changes of HPV infection [low-grade lesion] and precancer), p16 immunohistochemical staining is recommended to help clarify the situation. Strong and diffuse block-positive p16 results support a categorization of precancer. Negative or non-block-positive staining strongly favors an interpretation of low-grade disease or a non-HPV-associated pathology. 3. p16 is recommended for use as an adjudication tool for cases in which there is a professional disagreement in histologic specimen interpretation, with the caveat that the differential diagnosis includes a precancerous lesion . 4. WG4 recommends against the use of p16 immunohistochemical staining as a routine adjunct to histologic assessment of biopsy specimens with morphologic interpretations of negative, -IN 1, and -IN 3. a. Special Circumstance: p16 immunohistochemistry (IHC) is recommended as an adjunct to morphologic assessment for biopsy specimens interpreted as ≤-IN 1 that are at high risk for missed high grade disease, which is defined as a prior cytologic interpretation of HSIL, high grade atypical squamous cells (ASC-H), atypical squamous cells of undetermined significance (ASC-US)/HPV-16+, or atypical glandular cells not otherwise specified (AGC [NOS]). Comment: Any identified p16-positive area must meet H&E morphologic criteria for a high-grade lesion to be reinterpreted as such.
Clinical Algorithm(s)
Algorithms for biomarkers in human papillomavirus (HPV)-associated lower anogenital squamous lesions are available in a separate document (see the "Availability of Companion Documents" field). To create a histopathologic nomenclature system that reflects current knowledge of human papillomavirus (HPV) biology, optimally uses available biomarkers, and facilitates clear communication across different medical specialties The project had several specific objectives carried out by 5 work groups:
To develop a historical perspective of the origins of terminologies in the lower anogenital tract, with an emphasis on how nomenclature has influenced management To address whether the biology of HPV-associated disease in all of these sites allowed for unification of terminology To propose terminology for intraepithelial lesions and early invasive carcinoma To perform a review to determine whether currently available biomarkers support any proposed terminology recommendations or improve diagnostic reliability and reproducibility of histopathologic interpretation To facilitate and monitor dissemination and implementation of terminology changes into clinical practice with the goal of optimizing educational, quality assurance, regulatory, and clinical processes Each identified article underwent an inclusion-exclusion process, dual-independent reviews conducted by co-chairs and WG members. On the basis of each WG's inclusion-exclusion criteria, articles were kept for full data extraction, as "'indirect background material,"' or excluded from further review. Articles with 2 differing votes were considered in "'conflict."' Conflicts were adjudicated by both reviewers for WG2 and WG3 and by co-chair referees when conflicts could not be resolved. Co-chairs alone adjudicated WG4 conflicts. Conflicts included the "uncertain" reviews at the title/abstract level and the "indirect background material" reviews at the full text level. 
Number of Source Documents

Description of Methods Used to Formulate the Recommendations
A consensus process was convened to recommend terminology unified across lower anogenital sites. The goal was to create a histopathologic nomenclature system that reflects current knowledge of HPV biology, optimally uses available biomarkers, and facilitates clear communication across different medical specialties. The Lower Anogenital Squamous Terminology (LAST) Project was designed to comprehensively evaluate the terminology of human papillomavirus (HPV)-associated squamous lesions of the lower anogenital tract (LAT), including the cervix, the vagina, the vulva, the perianus, the anus, the penis, and the scrotum. The LAST Project included 5 working groups; 3 work groups performed comprehensive literature reviews and developed draft recommendations. Another work group provided the historical background and the fifth will continue to foster implementation of the LAST recommendations. Recommendations for terminology of squamous intraepithelial lesions (WG2) and superficially invasive squamous carcinomas (WG3) were based on the expert opinion of WG members and advisors after their comprehensive review of the literature. The recommendations from WG4, on use of biomarkers, were chiefly driven by the specific data from the comprehensive literature review. Based on the reviewer's overall assessment of the quality of the evidence for test characteristics and observer variability, Work Group 4's recommendations were framed using "recommend" if the recommendations are unlikely to change based on further evidence, and "suggest" if the recommendations are most likely correct but could be better supported by additional data.
At the consensus conference, WG members and advisors, along with representatives from 35 participating organizations (see Table 5 , Supplemental Digital Content; see the "Availability of Companion Documents" field) and observers, deliberated on, revised, and voted on the final draft recommendations; observers did not vote. At least a two-thirds majority (67%) was required for passage of each recommendation. The LAST Project writing committee was tasked with adding to the documentation the appropriate supporting detail and explanatory material for the recommendations.
See the Supplemental Digital Content (see the "Availability of Companion Documents" field) for more information on panel composition and methods used to produce recommendations.
Rating Scheme for the Strength of the Recommendations
Not applicable
Cost Analysis
A formal cost analysis was not performed and published cost analyses were not reviewed. The College of American Pathologists developed the Pathology and Laboratory Quality Center as a forum to create and maintain evidence-based practice guidelines and consensus statements. Practice guidelines and consensus statements reflect the best available evidence and expert consensus supported in practice. They are intended to assist physicians and patients in clinical decision-making and to identify questions and settings for further research. With the rapid flow of scientific information, new evidence may emerge between the time a practice guideline or consensus statement is developed and when it is published or read. Guidelines and statements are not continually updated and may not reflect the most recent evidence. Guidelines and statements address only the topics specifically identified therein and are not applicable to other interventions, diseases, or stages of diseases. Furthermore, guidelines and statements cannot account for individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge, to determine the best course of treatment for the patient. Accordingly, adherence to any practice guideline or consensus statement is voluntary, with the ultimate determination regarding its application to be made by the physician in light of each patient's individual circumstances and preferences. CAP and ASCCP assume no responsibility for any injury or damage to persons or property arising out of or related to any use of this statement or for any errors or omissions.
Method of Guideline Validation
Implementation of the Guideline
Description of Implementation Strategy Implications and Implementation of Standardized Terminology -Work Group 5
The overall scope and purpose of Work Group 5 was to address the potential implications of the Lower Anogenital Squamous Terminology (LAST) Project recommendations and to develop and initiate action plans for implementation of the recommendations.
Effective communication is absolutely necessary for widespread acceptance and adoption to occur. As with the Bethesda System terminology for gynecologic cytology, widespread communication of the benefits of changing and unifying terminology was necessary before adoption occurred. To communicate to these communities of interest, the Work Group recommended sustained organizational support to aid in the dissemination of the LAST recommendations. Specific actions include support for guideline publication; promote editorial commentaries for journals in related fields; present summary recommendations at scientific meetings; produce educational materials for professionals and patients; and develop a Web site that will include reference images, sample reports, and a self-test.
One of the major concerns raised by the clinical community regards management of cervical lesions in young women. The American Society for Colposcopy and Cervical Pathology (ASCCP) will address specific issues related to its clinical management guidelines in the near future. A potential reconciliation of the LAST terminology and the 3-tiered cervical intraepithelial neoplasia (CIN) system with current clinical management is represented in Figure 20 of the original guideline document.
Many of these recommendations have already been initiated and will continue to be developed further. It is also imperative to have liaison with professional organizations to assess current practice regarding use of LAST terminology for squamous human papillomavirus (HPV)-associated lesions and associated biomarker usage and to monitor adoption of the LAST recommendations.
Implementation Tools
Clinical Algorithm 
